亿腾嘉和：EDP167 II期临床试验完成首例受试者给药

Core Viewpoint - Eton Pharma (06998) announced the successful completion of the first dosing of the EDP167 Phase II clinical trial for patients with homozygous familial hypercholesterolemia (HoFH) [1] Group 1: Clinical Trial Details - The EDP167 Phase II clinical trial is a multicenter, dose-exploration, open-label study aimed at evaluating the efficacy and safety of EDP167 in adult patients with HoFH [1] - The primary endpoint of the trial is the change in low-density lipoprotein cholesterol (LDL-C) levels from baseline after 24 weeks of the first dosing [1] - The evaluation of the primary endpoint is expected to be completed by the fourth quarter of 2026 [1]